Skip To Main Content
Zemyna Kurnickaite on Muck Rack

Zemyna Kurnickaite

As seen in: Future Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Zemyna

Contact Zemyna, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Blood direct PCR: impact of CYP2C19 and CYP4F2 variants for bleeding prediction in ST-elevation myocardial infarction patients with ticagrelor

|
By Vacis Tatarunas, Ali Aldujeli, Zemyna Kurnickaite, Laurynas Maciulevicius
| Future Medicine Verified
Today ticagrelor is one of the main antiplatelet drugs in preventing secondary events after percutaneous coronary intervention (PCI). Current guidelines of the European Society of Cardiology recommend dual antiplatelet therapy (DAPT) with ticagrelor and aspirin over clopidogrel and aspirin DAPT [1]. Compared with clopidogrel, ticagrelor is a newer, third-generation drug.
Open in Who Shared Issue with article?
See all 1 articles